These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

723 related items for PubMed ID: 28494529

  • 21. [Non-alcoholic liver disease - diagnosis and treatment].
    Sarosiekjeznach-Steinhagen A, Ostrowska J, Czerwonogrodzka-Senczyna A, Boniecka I.
    Pol Merkur Lekarski; 2017 Nov 23; 43(257):237-242. PubMed ID: 29231919
    [Abstract] [Full Text] [Related]

  • 22. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
    He XX, Wu XL, Chen RP, Chen C, Liu XG, Wu BJ, Huang ZM.
    PLoS One; 2016 Nov 23; 11(10):e0162368. PubMed ID: 27711128
    [Abstract] [Full Text] [Related]

  • 23. Ameliorative potential of omega 3 fatty acids and HMG-CoA reductase inhibitors on experimentally-induced non-alcoholic steatohepatitis.
    Kabel AM, Abd Elmaaboud MA, Albarraq AA.
    Prostaglandins Leukot Essent Fatty Acids; 2015 May 23; 96():1-9. PubMed ID: 25541279
    [Abstract] [Full Text] [Related]

  • 24. Cancer-related gene expression is associated with disease severity and modifiable lifestyle factors in non-alcoholic fatty liver disease.
    Arendt BM, Teterina A, Pettinelli P, Comelli EM, Ma DWL, Fung SK, McGilvray ID, Fischer SE, Allard JP.
    Nutrition; 2019 Jun 23; 62():100-107. PubMed ID: 30870804
    [Abstract] [Full Text] [Related]

  • 25. [Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis].
    Heebøll S, Kazankov K, Poulsen MK, Vilstrup H, Grønbæk H.
    Ugeskr Laeger; 2012 Feb 20; 174(8):488-90. PubMed ID: 22348670
    [Abstract] [Full Text] [Related]

  • 26. Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial.
    Nogueira MA, Oliveira CP, Ferreira Alves VA, Stefano JT, Rodrigues LS, Torrinhas RS, Cogliati B, Barbeiro H, Carrilho FJ, Waitzberg DL.
    Clin Nutr; 2016 Jun 20; 35(3):578-86. PubMed ID: 26047766
    [Abstract] [Full Text] [Related]

  • 27. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis.
    Ji HF, Sun Y, Shen L.
    Nutrition; 2014 Sep 20; 30(9):986-91. PubMed ID: 24976430
    [Abstract] [Full Text] [Related]

  • 28. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.
    Ganesh S, Rustgi VK.
    Clin Liver Dis; 2016 May 20; 20(2):351-64. PubMed ID: 27063274
    [Abstract] [Full Text] [Related]

  • 29. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.
    Ahmed A, Wong RJ, Harrison SA.
    Clin Gastroenterol Hepatol; 2015 Nov 20; 13(12):2062-70. PubMed ID: 26226097
    [Abstract] [Full Text] [Related]

  • 30. Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.
    Jump DB, Lytle KA, Depner CM, Tripathy S.
    Pharmacol Ther; 2018 Jan 20; 181():108-125. PubMed ID: 28723414
    [Abstract] [Full Text] [Related]

  • 31. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.
    Eshraghian A.
    World J Gastroenterol; 2017 Nov 14; 23(42):7495-7504. PubMed ID: 29204050
    [Abstract] [Full Text] [Related]

  • 32. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
    Paschos P, Athyros VG, Tsimperidis A, Katsoula A, Grammatikos N, Giouleme O.
    Curr Vasc Pharmacol; 2018 Nov 14; 16(3):269-275. PubMed ID: 28676018
    [Abstract] [Full Text] [Related]

  • 33. The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease.
    Del Ben M, Polimeni L, Baratta F, Pastori D, Angelico F.
    Br J Clin Pharmacol; 2017 Jan 14; 83(1):88-95. PubMed ID: 26852185
    [Abstract] [Full Text] [Related]

  • 34. Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients?
    Musso G, Anty R, Petta S.
    Curr Pharm Des; 2013 Jan 14; 19(29):5297-313. PubMed ID: 23394094
    [Abstract] [Full Text] [Related]

  • 35. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.
    Said A, Akhter A.
    Ann Hepatol; 2017 Jan 14; 16(4):538-547. PubMed ID: 28611274
    [Abstract] [Full Text] [Related]

  • 36. Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD.
    Nobili V, Alisi A, Musso G, Scorletti E, Calder PC, Byrne CD.
    Crit Rev Clin Lab Sci; 2016 Jan 14; 53(2):106-20. PubMed ID: 26463349
    [Abstract] [Full Text] [Related]

  • 37. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.
    Le TA, Loomba R.
    J Clin Exp Hepatol; 2012 Jun 14; 2(2):156-73. PubMed ID: 25755424
    [Abstract] [Full Text] [Related]

  • 38. Role of Cholesterol-Associated Steatohepatitis in the Development of NASH.
    Horn CL, Morales AL, Savard C, Farrell GC, Ioannou GN.
    Hepatol Commun; 2022 Jan 14; 6(1):12-35. PubMed ID: 34558856
    [Abstract] [Full Text] [Related]

  • 39. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.
    Musso G, Cassader M, Paschetta E, Gambino R.
    JAMA Intern Med; 2017 May 01; 177(5):633-640. PubMed ID: 28241279
    [Abstract] [Full Text] [Related]

  • 40. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.
    Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F.
    Cochrane Database Syst Rev; 2007 Jan 24; (1):CD005166. PubMed ID: 17253544
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.